The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Silence Strengthens US Patent Estate

24 Jul 2017 07:00

RNS Number : 8200L
Silence Therapeutics PLC
24 July 2017
 

Silence strengthens US patent estate

 

24 July 2017

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that a further key US patent US 9,695,423 has been granted to Silence this month.

 

As previously announced on 30 May 2017, the US Patent Office issued a notice of allowance for US patent application 14/977,710, which has now issued as US patent US 9,695,423. This US patent provides further protection for Silence's innovative chemical modification technology in the US. Silence believes that the granted claims are relevant to third party medicines in ongoing clinical trials.

 

Chemical modification technology is vital to prevent the degradation of therapeutic short interfering RNA (siRNA) molecules and to enable potent RNA interference (RNAi). The use of such technology has a substantial impact on the performance of RNAi based drugs and as such is also used in third party RNAi medicines.

 

Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:

 

"The grant of US 9,695,423 is further confirmation by the US Patent Office of the validity of our patent claims that protect our innovative chemical modification technology. As previously stated, we will consider potential licences under our patent estate, which could have a significant financial effect relative to the current market capitalisation of Silence."

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

Tel: +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

 

Tel: +44 (0) 20 3727 1000

 

 

Notes to Editors

 

About Silence Therapeutics plc

 

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBSGDRLUDBGRX
Date   Source Headline
17th May 20115:39 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
16th May 20113:36 pmPRNGrant of options and warrants
16th May 20112:30 pmPRNResult of General Meeting
16th May 20117:00 amPRNResults of Placing and Open Offer
12th May 20115:42 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
27th Apr 20117:06 amPRNPlacing and Open Offer of New Ordinary Shares
27th Apr 20117:01 amPRNFull Year Results for the Year Ended 31 December 2010
26th Apr 20114:40 pmRNSSecond Price Monitoring Extn
26th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20114:40 pmRNSSecond Price Monitoring Extn
7th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20111:37 pmRNSTR-1: Notification of Major Interest in Shares
4th Apr 20114:40 pmRNSSecond Price Monitoring Extn
4th Apr 20114:35 pmRNSPrice Monitoring Extension
21st Mar 20118:00 amRNSPF-04523655 Phase 2 Study Results
14th Feb 20114:35 pmRNSPrice Monitoring Extension
7th Feb 20117:00 amRNSOffer Update
21st Dec 20107:00 amRNSYear-end Update
17th Nov 20104:40 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
16th Nov 20104:40 pmRNSSecond Price Monitoring Extn
16th Nov 20104:35 pmRNSPrice Monitoring Extension
15th Nov 20104:40 pmRNSSecond Price Monitoring Extn
15th Nov 20104:35 pmRNSPrice Monitoring Extension
12th Nov 20102:53 pmPRNForm 8.3 - Silence Therapeutics Plc
12th Nov 20101:35 pmBUSForm 8.3 - Silence Therapeutics plc
11th Nov 20101:54 pmPRNForm 8.3 - Silence Therapeutics Plc
11th Nov 201011:49 amRNSHolding in Company
11th Nov 20107:28 amBUSForm 8.3 - Silence Therapeutics plc
5th Nov 20104:40 pmRNSSecond Price Monitoring Extn
5th Nov 20104:35 pmRNSPrice Monitoring Extension
22nd Oct 20107:53 amBUSForm 8.3 - Silence Therapeutics plc
21st Oct 20109:23 amBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20103:35 pmBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20107:00 amRNSSilence Therapeutics Receives European RNAi Patent
19th Oct 20101:21 pmBUSForm 8.3 - Silence Therapeutics plc
18th Oct 20104:40 pmRNSSecond Price Monitoring Extn
18th Oct 20104:35 pmRNSPrice Monitoring Extension
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20102:28 pmBUSForm 8.3 - Silence Therapeutics plc
15th Oct 20101:52 pmBUSForm 8.3 - Silence Therapeutics plc
12th Oct 20104:35 pmRNSPrice Monitoring Extension
11th Oct 20105:04 pmBUSForm 8.3 - Silence Therapeutics plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.